WO2011053789A3 - Composition pharmaceutique et procédés pour améliorer la reconnaissance de lymphocytes t cytotoxiques et maintenir la mémoire à lymphocytes t contre une maladie pathogène - Google Patents

Composition pharmaceutique et procédés pour améliorer la reconnaissance de lymphocytes t cytotoxiques et maintenir la mémoire à lymphocytes t contre une maladie pathogène Download PDF

Info

Publication number
WO2011053789A3
WO2011053789A3 PCT/US2010/054726 US2010054726W WO2011053789A3 WO 2011053789 A3 WO2011053789 A3 WO 2011053789A3 US 2010054726 W US2010054726 W US 2010054726W WO 2011053789 A3 WO2011053789 A3 WO 2011053789A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
maintain
methods
pharmaceutical composition
memory against
Prior art date
Application number
PCT/US2010/054726
Other languages
English (en)
Other versions
WO2011053789A2 (fr
Inventor
James Cameron Oliver
Original Assignee
James Cameron Oliver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James Cameron Oliver filed Critical James Cameron Oliver
Publication of WO2011053789A2 publication Critical patent/WO2011053789A2/fr
Publication of WO2011053789A3 publication Critical patent/WO2011053789A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés et des compositions pharmaceutiques comprenant une séquence peptidique d'angiotensine I endogène ou des fragments biologiquement actifs de celle-ci en combinaison avec un antigène ou une partie immunogène d'un antigène pour induire une réponse à lymphocytes T cytotoxiques robuste et maintenir une mémoire à lymphocytes T cytotoxiques antigène-spécifique persistante, et leurs utilisations pour traiter ou prévenir des affections pathogènes.
PCT/US2010/054726 2009-10-30 2010-10-29 Composition pharmaceutique et procédés pour améliorer la reconnaissance de lymphocytes t cytotoxiques et maintenir la mémoire à lymphocytes t contre une maladie pathogène WO2011053789A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25676009P 2009-10-30 2009-10-30
US61/256,760 2009-10-30

Publications (2)

Publication Number Publication Date
WO2011053789A2 WO2011053789A2 (fr) 2011-05-05
WO2011053789A3 true WO2011053789A3 (fr) 2011-09-15

Family

ID=43923001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054726 WO2011053789A2 (fr) 2009-10-30 2010-10-29 Composition pharmaceutique et procédés pour améliorer la reconnaissance de lymphocytes t cytotoxiques et maintenir la mémoire à lymphocytes t contre une maladie pathogène

Country Status (1)

Country Link
WO (1) WO2011053789A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547366A4 (fr) 2010-03-18 2013-08-07 Univ Colorado State Res Found Agents d'inhibition des cellules myéloïdes suppressives
WO2014116587A1 (fr) * 2013-01-23 2014-07-31 University Of Southern California Stimulation de vaccination par des peptides d'angiotensine
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014134621A2 (fr) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Procédés et compositions permettant d'améliorer une réponse immunitaire, de bloquer la migration des monocytes, d'amplifier l'immunité d'un vaccin et d'inhiber la croissance d'une tumeur et des métastases
DK3394247T3 (da) * 2015-12-23 2021-04-12 Medigene Immunotherapies Gmbh Ny generering af antigen-specifikke tcr'er
WO2019238962A1 (fr) * 2018-06-14 2019-12-19 University College Cork - National University Of Ireland, Cork Peptide pour le traitement de maladies
CN114891074B (zh) * 2022-05-10 2023-04-11 中山大学·深圳 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165141A1 (en) * 2000-07-13 2002-11-07 Dizerega Gere S. Methods for promoting dendritic cell proliferation or differentiation
US20070053923A1 (en) * 2003-01-30 2007-03-08 Ki-Seok Park Dna vaccine composition with enhanced immunogenicity
US20080311138A1 (en) * 2004-12-13 2008-12-18 Maria Teresa De Magistris Adjuvant Activity of Gastrointestinal Peptides
WO2009023714A2 (fr) * 2007-08-14 2009-02-19 Thymon, Llc Compositions et procédés pour le traitement et la prophylaxie de l'hypertension

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165141A1 (en) * 2000-07-13 2002-11-07 Dizerega Gere S. Methods for promoting dendritic cell proliferation or differentiation
US20070053923A1 (en) * 2003-01-30 2007-03-08 Ki-Seok Park Dna vaccine composition with enhanced immunogenicity
US20080311138A1 (en) * 2004-12-13 2008-12-18 Maria Teresa De Magistris Adjuvant Activity of Gastrointestinal Peptides
WO2009023714A2 (fr) * 2007-08-14 2009-02-19 Thymon, Llc Compositions et procédés pour le traitement et la prophylaxie de l'hypertension

Also Published As

Publication number Publication date
WO2011053789A2 (fr) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2011053789A3 (fr) Composition pharmaceutique et procédés pour améliorer la reconnaissance de lymphocytes t cytotoxiques et maintenir la mémoire à lymphocytes t contre une maladie pathogène
EP3533461A3 (fr) Peptides dérivés de prame et compositions immunogènes les comportant
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EP2896632A3 (fr) Matériau et procédés de traitement ou de prévention de maladies associées à des HER-3
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
EP2583976A3 (fr) Vaccins avec SEQ ID NO: 210, 196, 202, 213, 214, 214 ou 223 de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2528934A4 (fr) Peptides aromatiques-cationiques et leurs utilisations
PH12013502192A1 (en) Antibodies against human angiopoietin 2
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
WO2012027379A3 (fr) Vaccins contre le cancer du cerveau à base de peptides alpha-2 du récepteur de l'interleukine 13
WO2009025196A1 (fr) Peptide foxm1 et agent médicinal le comprenant
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EP3311833A3 (fr) Compositions induisant l'aide des lymphocytes t
GB2496794A (en) Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
WO2014165607A3 (fr) Formulations peptidiques cationiques aromatiques, compositions et procédés d'utilisation
WO2008124646A3 (fr) Utilisation de protéines amyloïdes en tant qu'échafaudages pour des vaccins
WO2011159814A3 (fr) Nouveaux vaccins de rappel recombinants vivants
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
RU2017132324A (ru) Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
WO2009047513A3 (fr) Composé, utilisation et procédé
WO2009132231A3 (fr) Peptidyl-diacylglycérides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10827527

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10827527

Country of ref document: EP

Kind code of ref document: A2